HCWB Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
My Notes
Capture your thoughts, links and company narrative
HCW Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$2.52 |
| 52 Week Low | US$0.28 |
| Beta | 0.89 |
| 1 Month Change | -25.14% |
| 3 Month Change | -18.25% |
| 1 Year Change | -65.17% |
| 3 Year Change | -82.66% |
| 5 Year Change | n/a |
| Change since IPO | -93.37% |
Recent News & Updates
Shareholder Returns
| HCWB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.2% | 2.1% | 2.8% |
| 1Y | -65.2% | -3.8% | 24.5% |
Return vs Industry: HCWB underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: HCWB underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| HCWB volatility | |
|---|---|
| HCWB Average Weekly Movement | 92.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HCWB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HCWB's weekly volatility has increased from 48% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 45 | Hing Wong | www.hcwbiologics.com |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.
HCW Biologics Inc. Fundamentals Summary
| HCWB fundamental statistics | |
|---|---|
| Market cap | US$17.73m |
| Earnings (TTM) | -US$37.33m |
| Revenue (TTM) | US$3.50m |
5.3x
P/S Ratio-0.5x
P/E RatioIs HCWB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCWB income statement (TTM) | |
|---|---|
| Revenue | US$3.50m |
| Cost of Revenue | US$7.61m |
| Gross Profit | -US$4.12m |
| Other Expenses | US$33.21m |
| Earnings | -US$37.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | -117.76% |
| Net Profit Margin | -1,067.83% |
| Debt/Equity Ratio | -129.7% |
How did HCWB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:49 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HCW Biologics Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Okunewitch | Maxim Group |